Amgen’s Repatha cholesterol shot slashed heart attack risk by 36%
Elizabeth Cooney, a cardiovascular disease reporter at STAT, recently covered a groundbreaking study on a cholesterol-lowering injection called Repatha. The study, published in the New England Journal of Medicine and presented at the American Heart Association’s scientific sessions in New Orleans, revealed the significant impact of Repatha on reducing cardiovascular events in individuals at high risk who have not yet experienced a heart attack or stroke.
The research indicated that Repatha decreased coronary heart disease death, heart attack, and stroke by 25% overall and reduced first heart attacks by 36% in individuals with high cholesterol but no prior history of these serious events. These participants were already taking statins or other cholesterol-lowering medications due to their high cholesterol levels.
Repatha, developed by Amgen, also demonstrated effectiveness in lowering cardiovascular problems and preventing the need for stent and bypass procedures. This success in meeting both endpoints of the clinical trial, known as VESALIUS-CV, surpassed the outcomes of statin therapy, which had been the standard treatment for high cholesterol and cardiovascular risk for many years.
The study’s findings underscore the potential of Repatha as a game-changer in the management of cardiovascular health for individuals at high risk. The injection’s ability to significantly reduce the incidence of heart attacks, strokes, and other cardiovascular events could revolutionize treatment strategies for this population.
As the medical community continues to explore innovative approaches to cardiovascular disease prevention and management, Repatha’s promising results offer hope for improved outcomes and quality of life for individuals at high risk of heart disease and stroke. This breakthrough in cholesterol-lowering therapy marks a significant advancement in the field of cardiovascular medicine, paving the way for more effective and personalized treatment options for patients facing these serious health challenges.
